How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to before it became an independent company, AbbVie has reliably given its investors rising dividends year after year.
Yet the challenges that drug companies face have gotten tougher recently, and some investors are nervous that AbbVie might face pressure to take actions that might threaten its dividend over the long run. Looking at AbbVie with an eye toward deciding whether the dividend is safe should reveal any lingering issues that could grow into big problems ahead.
Metric
Source: Fool.com
Amgen Inc. Aktie
334,10 €
-0,61 %
Deutliches Buy-Überwiegen bei Amgen Inc. im Vergleich zu Sell-Einschätzungen.
Trotz eines Kursziels von 332 €, das unter 334.1 € liegt, ergibt sich für Amgen Inc. ein negatives Potenzial von -0.63%.
